The Europe Antimicrobial Resistance Diagnostics Market would witness market growth of 5.4% CAGR during the forecast period (2022-2028).
Antibiotics, a bacteria-specific antimicrobial, are said to be one of the most significant therapeutic advancements in medical history. They have transformed how physicians care for people who have bacterial infections and also have helped to lower the morbidity and mortality associated with infectious diseases. They are also a crucial component of modern medicine, and without the provision of strong antibiotics, common treatments like transplantation, cancer chemotherapy, and even orthopedic surgery would not be possible.
These drugs, however, have a history of abuse. They are frequently taken for viral infections even though they don't work against them. Similar to inaccurate diagnoses, when the causal microorganism is unknown, broad-spectrum antibiotics, antibiotics that kill a lot of different bacteria rather than just the germs that cause the disease, are frequently recommended.
The pharmaceutical, veterinary, and agricultural sectors, as well as individuals at any stage of life, could be impacted by antimicrobial resistance. This makes the issue one of the most important public health issues on the entire planet. To be hazardous, fungi and bacteria do not necessarily need to be immune to all antibiotics or antifungals. Even a single drug resistance can lead to major issues. Infections that are resistant to first- and second-line antibiotics can affect the patient by resulting in serious side effects like organ failure and delaying treatment and recovery for weeks or even months.
The general decreases in antibiotic use seen in the European region over the past few years imply that concerted, region-wide efforts to promote the wise usage of antibiotics have been successful. Yet in 2020, the average community intake of broad-spectrum antibiotics medicines was 3.5 times higher than that of narrow-spectrum medicines, which are often the first line of treatment. Presently a wide range of AMR in bacteria from infections in humans across EU nations, such as E. faecalis' resistance to vancomycin or K. pneumoniae's and P. aeruginosa's and Acinetobacter species' resistance to carbapenems can be found. These provide significant opportunities to reduce AMR through measures that enhance infection control and prevention in addition to antimicrobial preservation practices. Hence, the usage of AMR diagnostics has increased, which has propelled the expansion of the antimicrobial resistance diagnostics market in the coming years.
The Germany market dominated the Europe Antimicrobial Resistance Diagnostics Market by Country in 2021; thereby, achieving a market value of $369.1 million by 2028. The UK market is exhibiting a CAGR of 4.6% during (2022 - 2028). Additionally, The France market would experience a CAGR of 6.2% during (2022 - 2028).
Based on Technology, the market is segmented into PCR, Immunoassay, NGS, Microbiology Culture, Mass Spectrometry, Rapid & Point of Care and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies & Others. Based on Pathogen, the market is segmented into Methicillin Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile (CD), Drug Resistant Campylobacter (DRC), Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Antimicrobial Resistance Diagnostics Market will Hit $5.7 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.
By Technology
By End User
By Pathogen
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
